New Study on Depression in Children and Adolescents Provides Insights on Antidepressant Side Effects

Strategic Insights -

Researchers from Kyoto University, in collaboration with other institutions, have conducted a study to better understand the side effects of newer-generation antidepressants in children and adolescents with major depressive disorder (MDD). The researchers aim to evaluate the specific adverse events (AEs) associated with these medications and their comparative tolerability. The study's findings will provide valuable information for clinicians and patients to make informed treatment decisions. According to the researchers, the burden of AEs is significant, as they can lead to treatment discontinuation and reduced adherence.

Key Takeaways:

  • The study aims to evaluate the side effect profile and comparative tolerability of 22 newer-generation antidepressants in children and adolescents with MDD.
  • The planned network meta-analysis will include double-blind randomized controlled trials that compared one active drug with another and/or placebo for the acute treatment of MDD.
  • The study will focus on primary outcomes such as the number of patients experiencing at least one AE, specific non-serious AEs, serious AEs (e.g., suicidal ideation), and AEs leading to treatment discontinuation.
  • The systematic search will include databases such as PubMed, Embase, Cochrane Library, Web of Science, and PsycInfo.
  • The researchers will use the R software to conduct the network meta-analysis and assess consistency through local and global methods.
  • The study's findings will be published in a peer-reviewed journal, such as BMJ Open, and presented at international conferences.

Statistics:

  • 22 newer-generation antidepressants will be evaluated in the study.
  • The study will include double-blind randomized controlled trials that compared one active drug with another and/or placebo for the acute treatment of MDD.
  • The systematic search will include 5 databases and regulatory agencies' registries.
  • The R software will be used to conduct the network meta-analysis and assess consistency.
  • The study will focus on primary outcomes that include the number of patients experiencing at least one AE, specific non-serious AEs, serious AEs (e.g., suicidal ideation), and AEs leading to treatment discontinuation.

Sources:

  • Furukawa TA, et al. (2025). Side effect profile and comparative tolerability of newer generation antidepressants in the acute treatment of major depressive disorder in children and adolescents: protocol for a systematic review and network meta-analysis. BMJ Open, 15(10).
  • Our reporters obtained a quote from the research from Kyoto University: "This is of high clinical importance, as AEs are burdensome for patients, can reduce treatment adherence and lead to discontinuation."